Huagai Capital
VC Fund
Beijing, China
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
- Total investments:
- 152
- Last investment:
- Lead investor:
- 41%
- Fund size:
- $430M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Huagai Capital invests in
Stages Huagai Capital invests in
Countries Huagai Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Angel
- $425k–$15M
- Series A
- $1.5M–$73M
- Series B
- $3.5M–$90M
Investment Focus
Industry
- Health Care 39 (26%)
- Biotechnology 30 (20%)
- Medical 29 (19%)
- Manufacturing 17 (11%)
- Pharmaceutical 16 (11%)
Stage
- Series A 51 (34%)
- Series B 29 (19%)
- Angel 16 (11%)
- Series C 13 (9%)
- Seed 12 (8%)
Country
- China 119 (78%)
- United States 6 (4%)
- Hong Kong 2 (1%)
- Germany 1 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Lu Binghui
President & Co-Founder
|
President & Co-Founder | Total investments: 0 | Find email | |
|
Meng Nan
Executive General Manager
|
Executive General Manager | Total investments: 1 | Find email | |
Wang Shaokun
Vice President
|
Vice President | Total investments: 1 | Find email | |
Xiaolin Xu
Chairman & Co-founder
|
Chairman & Co-founder | Total investments: 3 | Find email | |
Zeng Zhiqiang
Managing Partner
|
Managing Partner | Total investments: 4 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
SeaArt
|
SeaArt is an AI creativity platform that provides tools for generating and editing images, videos, audio, and interactive AI character chats. The service includes text-to-image art generation, text-to-video and image-to-video creation, and an AI chatbot assistant with customizable characters. SeaArt also offers AI audio synthesis with multiplevoices, workflow control through ComfyUI, model training and hosting for Stable Diffusion based models, and swift AI tools for upscaling and filtering media. A built-in community enables sharing, remixing, challenges, and creator incentive programs for monetizing AI-generated works. | $14.7M / Series B / Jul 13, 2026 | |
GigaAI
|
Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space. | $147.9M / Series B / Jun 15, 2026 | |
Falcon Technology
|
Falcon Technology focuses on DSA processor design innovation, developing a dedicated computing technology ecosystem based on the RISC-V architecture to deliver high-performance, energy-efficient processing solutions for next-generation intelligent computing applications. | $14.7M / Angel / May 20, 2026 | |
SenseTime
|
SenseTime Medical is an AI healthcare firm that creates solutions for hospitals, research institutions, and the global medical market. Through its SenseCare platform, the company provides over 40 specialized AI modules and maintains strategic partnerships with organizations like Roche, Midea, and Ruijin Hospital to streamline patient services andmedical innovation. | $73.3M / Series A / Apr 20, 2026 | |
PrinoPharma
|
PrinoPharma focuses on developing novel druggable sites targeting difficult-to-drug or existing druggable targets. | $14.5M / Angel / Mar 10, 2026 | |
QL Biopharma
|
QL Biopharma focuses on developing innovative drugs and premium me-too drugs targeting metabolic diseases. | $72.8M / Series C / Mar 02, 2026 | |
|
Shanghai Genentech Biotech Co.
|
$28.4M / Private Equity / Dec 16, 2025 | ||
Synaire
|
Synaire engaged in the research and development, production and other related businesses of home ventilators, oxygen concentrators, and non-invasive ventilators. | Seed / Dec 12, 2025 | |
Hyperway Pharm
|
Hyperway Pharm is a pharmaceutical R&D and production enterprise with R&D as the core driving force. It adheres to the philosophy of “Hai Na Baichuan, Bocai, Changzhi, Good People, and Great Deeds”, and is committed to building a world-leading research and development platform for small molecule innovative drugs and high-end APIs. Researchand development platform for research and development platforms and high-tech barriers. Its core founding team is a special high-end talent in Chengdu, Sichuan Province, and has many Fortune 500 companies such as Bayer, Johnson & Johnson, Sanofi and Merck, as well as “Kingming Kant”. Work experience of domestic well-known pharmaceutical companies such as “Hengrui”, “Yangzijiang”, “Hai Cisco”, “Smart Chemical” and “Bite Pharmaceutical”, with rich experience in international and domestic drug development and management, and led the team. It has successively developed a number of world-class innovative drugs (which have entered clinical trials) and a number of high-end high-end generic drugs | $28.1M / Series B / Oct 22, 2025 | |
Moyang Biotechnology
|
Moyang Biotechnology specializes in the development and consulting services of medical biomaterials for beauty sector. | Series C / Aug 08, 2025 | |
| See all 152 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Huagai Capital invest in?
Huagai Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 152 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Huagai Capital's check size?
Huagai Capital typically joins rounds of $425k–$15M at Angel, $1.5M–$73M at Series A and $3.5M–$90M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Huagai Capital participates in.
How do I contact Huagai Capital?
Public channels for Huagai Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Huagai Capital?
The team at Huagai Capital includes Lu Binghui (President & Co-Founder), Meng Nan (Executive General Manager) and Wang Shaokun (Vice President). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
